Patents Assigned to OXFORD BIOTHERAPEUTIC LTD.
-
Publication number: 20130156788Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.Type: ApplicationFiled: December 27, 2012Publication date: June 20, 2013Applicants: OXFORD BIOTHERAPEUTICS LTD, MEDAREX, INC.Inventors: Medarex, Inc., Oxford BioTherapeutics Ltd
-
Patent number: 8420084Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.Type: GrantFiled: March 5, 2010Date of Patent: April 16, 2013Assignees: Medarex, Inc., Oxford BioTherapeutics LtdInventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
-
Patent number: 8420091Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.Type: GrantFiled: February 7, 2010Date of Patent: April 16, 2013Assignees: Oxford BioTherapeutics Ltd., Medarex, Inc.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Publication number: 20120231004Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to the Ephrin type-A receptor 10 with high affinity. Nucleic acid molecules encoding the Ephrin type-A receptor 10 antibodies, expression vectors, host cells and methods for expressing the Ephrin type-A receptor 10 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Ephrin type-A receptor 10 antibodies are also provided. Methods for detecting the Ephrin type-A receptor 10, as well as methods for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer are disclosed.Type: ApplicationFiled: October 13, 2010Publication date: September 13, 2012Applicant: OXFORD BIOTHERAPEUTIC LTD.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120114672Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed.Type: ApplicationFiled: April 20, 2010Publication date: May 10, 2012Applicant: OXFORD BIOTHERAPEUTICS LTD.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Publication number: 20120093826Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.Type: ApplicationFiled: March 5, 2010Publication date: April 19, 2012Applicants: OXFORD BIOTHERAPEUTICS LTD, MEDAREX, INC.Inventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
-
Publication number: 20120058131Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.Type: ApplicationFiled: January 21, 2010Publication date: March 8, 2012Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Patent number: 8084034Abstract: The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer treatment, and in drug development. Also provided are antibodies (and other affinity reagents such as Affibodies) which interact with or modulate the expression or activity of the polypeptides.Type: GrantFiled: August 26, 2009Date of Patent: December 27, 2011Assignee: Oxford BioTherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20110229480Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer, for monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer treatment, and for drug development.Type: ApplicationFiled: September 3, 2009Publication date: September 22, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Publication number: 20110195074Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development.Type: ApplicationFiled: June 9, 2009Publication date: August 11, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Publication number: 20110027173Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: ApplicationFiled: December 24, 2008Publication date: February 3, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps